Therefore, the primary clinical relevance of TRPM4 and SLC9A1 in breast cancer is more robustly underscored by their frequent mRNA/protein overexpression and strong association with poor prognosis, as demonstrated throughout our study, rather than by their mutational status. This evidence concerns the gene TRPM4 and breast cancer.